New funding will support development of personalized cell therapies for compromised patient populations
A Biomedical Catalyst Primer Award will fund research into low transfection efficient in patients with already highly compromised cell populations.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>